Champions Biotechnology Partners with Gradalis Inc. and Mary Crowley Cancer Research Center to Develop Personalized Vaccines for Cancer Patients

Baltimore, MD – February 03, 2009 – Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a collaboration with Gradalis Inc. and Mary Crowley Cancer Research Center (MCCRC). The team will seek an Investigational New Drug (IND) permission from the U.S. Food and Drug Administration (FDA) to utilize Champions Biotechnology’s Biomerk Tumorgraft technology to develop personalized vaccines for cancer patients. Each vaccine is engineered to treat the patient’s specific cancer because it is developed from the patient’s own tumor.

“The close correlation between Biomerk Tumorgrafts and the human tumor they are derived from provide the basis for our predictive preclinical platform. This technology also enables us, in collaboration with Gradalis, to develop personalized vaccines for cancer patients,” said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. “Personalized vaccines offer a novel treatment option that is customized to each individual’s unique cancer but can rarely be produced due to insufficient cells from accessible tumor tissue. We are pleased to enter into this agreement with Gradalis and MCCRC that leverages the value of our unique platform.”

Under the terms of the agreement Gradalis Inc. will work toward the IND that is required to begin administering the individualized vaccine to patients at MCCRC in a Phase I clinical trial. Champions Biotechnology anticipates that the collaboration will result in a new, near term option for the growing number of physicians that are taking advantage of the Company’s Personalized Oncology services and a significant opportunity for the Company in any future commercialization of the technology.

For more information regarding Champions Biotechnology’s growing business and recent news, please visit